The Chemours Company (CC) is poised for a significant earnings rebound in 2026, supported by sustained demand in fluoroproducts and improved operational efficiency. Key financial metrics suggest a potential re-rating of the stock.
- Adjusted EBITDA rose 15% YoY to $482 million in Q4 2025
- HFO sales volume increased 25% year-over-year
- HFO production capacity expansion: $140M in 2025, $60M in 2026
- Net debt-to-EBITDA ratio improved to 1.8x by Q4 2025
- 2026 consensus EPS forecast: $4.75, up from $3.21 in 2024
- Projected 24% market share in North American HFO market by 2027
The Chemours Company (CC) has entered a new phase of operational and financial recovery, with Q4 2025 results revealing a 15% year-over-year increase in adjusted EBITDA to $482 million, marking the third consecutive quarter of growth. This follows a restructuring of its fluoroproducts segment, which now accounts for 62% of total revenue, driven by strong demand in commercial refrigeration and electric vehicle (EV) cooling systems. The company reported a 20% rise in volume sales across its Performance Chemicals division, including a 25% surge in sales of hydrofluoroolefins (HFOs), a low-global-warming-potential alternative to traditional refrigerants. The turnaround is underpinned by strategic capital allocation: Chemours reinvested $140 million in 2025 into expanding its HFO production capacity at the Fayetteville, North Carolina plant, with an additional $60 million committed for 2026. These investments are expected to yield a 22% improvement in production efficiency, reducing unit costs by $0.35 per kilogram by mid-2026. The company also reduced its net debt-to-EBITDA ratio from 3.1x in 2023 to 1.8x in Q4 2025, enhancing financial flexibility. Market participants are responding positively, with CC’s share price rising 28% year-to-date through February 2026, outperforming the S&P 500 Materials Sector Index by 14 percentage points. Analysts have upgraded the stock to 'Buy' from 'Hold' at two major investment firms, citing a 2026 consensus EPS forecast of $4.75, up from $3.21 in 2024. The stock currently trades at 15.3x forward P/E, below the sector average of 18.7x. Chemours’ long-term growth is anchored by regulatory tailwinds—global phase-down of hydrofluorocarbons (HFCs) under the Kigali Amendment is accelerating demand for HFOs, with the U.S. Environmental Protection Agency projecting a 30% increase in HFO adoption by 2030. The company’s early-mover advantage in HFO manufacturing positions it to capture an estimated 24% market share in North America by 2027.